ArticleScientific reports2023
Risk factors for arteriovenous fistula dysfunction in hemodialysis patients: a retrospective study.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Early balloon-assisted-maturation does not reduce patency of mature arteriovenous fistulae.Renal failure · 2026Article
- Review
- Association Between Blood Cobalt Levels and Arteriovenous Fistula Dysfunction in Patients Undergoing Maintenance Hemodialysis: A Multicenter Observational Study.Kidney medicine · 2026Article
- Dialysis on the Central Venous Catheter at the Time of Arteriovenous Fistula Creation Is Associated with Long-Term Vascular Access Failure.Journal of clinical medicine · 2026Article
- Article
- World Kidney Day as a Platform for Action: Early Outcomes of a Vascular Access Mission in Sub-Saharan Africa.Cureus · 2026Article
- Inhibition of smooth muscle phenotypic modulation by bardoxolone methyl, omaveloxolone, and cinnamaldehyde is Nrf-2 dependent.Advances in redox research · 2026Article
- Four-Year Outcomes of aXess Arteriovenous Conduit in Hemodialysis Patients: Insights from Two Case Reports of the aXess FIH Study.Journal of clinical medicine · 2025Article
- Analysis of arteriovenous fistula failure factors and construction of nomogram prediction model in patients with maintenance hemodialysis.Renal failure · 2025Article
- Needle-free vascular access port for hemodialysis: Proof-of-concept validation in an experimental animal study.Journal of vascular surgery cases and innovative techniques · 2025Article
- BACE2-Induced Aberrant Lymphatic Network Aggravates the Local Inflammation in Arteriovenous Fistulas With Hyperphosphatemia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Determinants of Patient Satisfaction with Vascular Access in Hemodialysis: Insights from a Multicenter Study in Italy.Clinics and practice · 2025Article
- Analysis of the efficacy of drug-coated balloons in the treatment of venous stenosis in hemodialysis access.BMC surgery · 2025Article
- Patterns and Outcomes of Permanent Vascular Access in End-Stage Kidney Disease: A Multicenter Experience.Cureus · 2025Article
- Hyperphosphatemia as a potential risk factor for arteriovenous fistula dysfunction: A retrospective study in hemodialysis patients.PloS one · 2025Article
- Association of Anatomical Location and Preoperative Blood Biomarkers With Arteriovenous Fistula Maturation in Hemodialysis Patients.International journal of vascular medicine · 2025Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Arteriovenous fistula (AVF) is the first choice of vascular access in hemodialysis (HD) patients. However, the correlations between patient factors and the arteriovenous fistula patency remain unclear. Therefore, our study investigates the risk factors associated with AVF dysfunction in HD patients. A total of 233 end-stage renal disease (ESDR) patients who met the study inclusion criteria in the Nephrology Department of Hunan Provincial People's Hospital between December 2020 and June 2022 were included in this study. The baseline demographic, clinical and laboratory parameters were collected at the time of AVF creation and analyzed. Of the 233 ESRD patients, 146 (62.7%) were male and the mean age was 56.11 ± 12.14 (21-82) years. The patients were followed for a median time of 14 months. Kaplan-Meier analysis showed a 6-, 12- and 24-month post-placement survival of 87.1%, 82.8% and 80.7%, respectively. Univariate Cox regression analysis revealed weight (HR, 1.03; P = 0.03) as a predictor for the loss of vascular access functionality. In addition, multivariate Cox regression analysis further demonstrated that sex (HR, 3.41; P = 0.03), weight (HR 1.08; P < 0.01) and phosphorus level (HR: 3.03; P = 0.01) are independent risk factors for AVF dysfunction. AVF dysfunction is highly associated with several risk factors including weight, phosphorus level, and sex. Positive intervention strategies targeting these potential factors, such as weight loss or oral phosphate binders could improve the long-term success of AVF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.